Product
INBRX-105
Aliases
INBRX-105 - PDL1x41BB antibody
1 clinical trial
9 indications
Indication
Metastatic Solid TumorsIndication
Lung CancerIndication
MelanomaIndication
Head and Neck Squamous Cell CarcinomaIndication
Stomach AdenocarcinomaIndication
Renal Cell CarcinomaIndication
Esophageal adenocarcinomaIndication
Nasopharyngeal CarcinomaIndication
Oral Cavity CancerClinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-08-01